AUPH News and Press, Aurinia Pharmaceuticals Inc

2024-08-01 13:52:05 ET Aurinia Pharmaceuticals, Inc. (AUPH) Q2 2024 Earnings Conference Call August 01, 2024, 08:30 ET Company Participants Andrea Christopher - Head, Corporate Communications & IR Peter Greenleaf - President, CEO & Director Greg Keenan - ...

Viridien ADR (CGGYD) is expected to report for Q2 2024 Civitas Resources Inc. (CIVI) is expected to report $2.9 for Q2 2024 Aptiv PLC (APTV) is expected to report $1.37 for Q2 2024 Ardelyx Inc. (ARDX) is expected to report $-0.1 for Q2 2024 Beazer Homes USA Inc. (BZH) is expected ...

2024-08-01 06:05:56 ET More on Aurinia Pharma Aurinia Pharmaceuticals Appears Undervalued Aurinia Pharma Q2 2024 Earnings Preview Seeking Alpha’s Quant Rating on Aurinia Pharma Historical earnings data for Aurinia Pharma Financial information f...

Company achieved $57.2 million in total net revenue and $55.0 million in net product revenue for the second quarter of 2024, representing year-over-year growth of approximately 38% and 34% respectively Company generated approximately $15.8 million in free cash flow in the second quarter a...

2024-07-31 12:14:24 ET More on Aurinia Pharma Aurinia Pharmaceuticals Appears Undervalued Aurinia Pharma: A Welcome Change To The Thesis (Rating Upgrade) Seeking Alpha’s Quant Rating on Aurinia Pharma Historical earnings data for Aurinia Pharma ...

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for the second quarter of 2024 on Thursday, August 1, 2024, before markets open. Aurinia’s management team will host a conference call/webcast at 8:30...

2024-07-05 14:10:21 ET Summary Aurinia Pharmaceuticals stock has dropped more than 80% due to disappointing Lupkynis sales since its launch in 2021. Management is focusing solely on driving Lupkynis sales and cutting costs by laying off 25% of its sales force and discontinuing oth...

2024-06-27 04:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced voting results for its 2024 annual general meeting (the Meeting) of shareholders held on June 14, 2024. Shareholders re-elected five of nine incumbent directors to the Board of Directors (the Board). The four...

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), today announced an oral presentation at the European Alliance of Associations for Rheumatology (EULAR) 2024 taking place in Vienna, Austria June 12-15. The data reinforces previous findings from the AURORA Clinical Program ...